The future of electrocardiography is autonomous ECG interpretation

Comprehensive AI for ambulatory ECG analysis

Our AI algorithm identifies more than 20 types of cardiac events, including key arrhythmias such as:

  • Atrial Fibrillation or Atrial Flutter

  • Atrioventricular Block (second-degree, third-degree, advanced high-grade AV block)

  • Ventricular Tachycardia

  • Premature Supraventricular Complexes (PSVCs) and PSVC Couplets, PSVC Triplets

  • Atrial Bigeminy, Atrial Trigeminy, Atrial Quadrigeminy.

  • Premature Ventricular Complexes (PVCs), Ventricular Couplets, Ventricular Triplets.

  • Ventricular Bigeminy, Ventricular Trigeminy, Ventricular Quadrigeminy.

  • Pause

  • Sinus Rhythm, Bradycardia, Tachycardia

ATRIAL FIBRILLATION DETECTION

>10x reduction in atrial fibrillation false positives from Holter ECG

Using the MIT-BIH public database, our PulseAI algorithm was compared to a reference RR interval-based method. Our AI algorithm was shown to improve the specificity in AFib detection from 79% to 99% with comparable sensitivity.

REDUCTION OF INCONCLUSIVE

A 95% reduction in inconclusive smartwatch ECG interpretations.

We conducted a comparative analysis between our PulseAI for smartwatch ECG and the embedded device algorithm. The findings revealed a 95% reduction in inconclusive diagnoses using PulseAI. This efficiency not only minimises the time required for physician review but also lowers the likelihood of missed, delayed, or inaccurate diagnoses.

QTc INTERVAL MEASUREMENT

39% increase in the number of patients who could measure the QTc interval on smartwatch ECG

PulseAI revolutionizes QTc-interval measurements by leveraging advanced AI technology to deliver superior accuracy and precision from single-lead ECGs. Compared to traditional manufacturer algorithms, PulseAI significantly improves diagnostic accuracy, ensuring more reliable assessments of critical cardiac metrics. This innovation enhances clinical decision-making, reducing the risk of errors and improving patient outcomes in cardiovascular care.

*The PulseAI Platform is not FDA cleared.